Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Sep 22, 2022 8:55am
91 Views
Post# 34978520

RE:Most promising…

RE:Most promising…

Great find as always Scarlett!
 

scarlet1967 wrote:

They filed the WO patent in February and it was published this month. Cancer stem cells as per latest research are present in various types of cancers including:

Breast, Colon, Ovary, Pancreas, Prostate, Melanoma, Multiple Myeloma, Non-melanoma skin cancer…

Although this research is early in the process it seems if and when they can duplicate the results in humans it can add significant value to the potential treatment against metastatic cancers.

From the patent application:

 

 

 

“Nearly all current cancer treatments focus on de-bulking tumors without targeting the most dangerous cells in the tumor: cancer stem cells (CSCs). CSCs are responsible for the spread of cancer cells throughout the body, the growth of tumors, cancer’s resistance to chemotherapy, and the recurrence of tumors after treatment or surgical removal, notably through their ability to arrest in the GO phase, giving rise to new tumors. Because current treatments do not target the CSC population, they frequently lead to the rise of resistant tumors and continued cancer spread. Therefore, CSCs could be considered the most promising targets for cancer treatment. There is thus a need for the development of strategies for the treatment of cancer, and more particularly cancers associated with CSCs, for example to overcome tumor resistance to cancer therapy, and prevent/treat cancer relapse and improve survival in cancer patients.”

 

https://patents.google.com/patent/WO2022178634A1/en

 



<< Previous
Bullboard Posts
Next >>